Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Experts have developed a new tool for surgical prioritization and ranking for patients with head and neck cancer in a scarce-resource settings associated with the COVID-19 pandemic.
Outcomes and survival improved for early-stage oropharyngeal cancer, but not other cancers.
Single-center study reports on the effects of oropharyngeal cancer treatment at 3, 6, and 12 months after chemoradiotherapy or radiotherapy alone, and with and without a feeding tube.
The social media platform can be useful as an education tool for oncologists to stay up to date on new research in oncology — but physicians still need to be mindful of the information sources.
The approval is based on evidence that the vaccine can prevent anogenital infections, with an ongoing trial looking at throat infection prevention in men likely to be critical for continued approval.
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes.
Patients treated with chemotherapy plus radiotherapy had a 64% reduced likelihood of disease progression or death compared with those who underwent chemotherapy alone.
The purpose of this study was to develop and test a gene-expression profiling assay to facilitate patient selection for induction chemotherapy in the setting of LA-NPC.
New research presented at ASCO 2020 sheds light on conflicts of interest among NCCN panelists and links industry dollars to measures of academic success among junior faculty.
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients.
Preclinical data has suggested that radiotherapy can increase sensitivity to immunotherapy and that immunotherapy can sensitize cancer cells to radiation.
The FDA has approved an expanded indication for Gardasil 9® (human papillomavirus 9-valent vaccine [HPV], recombinant; Merck) to include the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58 in patients aged 9 to 45 years.
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing.
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated.
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions.
The FDA has approved the supplemental Biologics License Application (sBLA) for Keytruda® (Merck) to include an additional recommended dosage of 400mg every 6 weeks across all adult indications.